



SB 202190 (CAS: 152121-30-7)

Catalog #: EBC51002

Biological Activity

Synonym(s) SB-202190, SB202190, FHPI, 4-[4-(4-Fluorphenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol

Chemical Name 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole

Application SB 202190 is an inhibitor of the isoforms p38α and p38β

 $\begin{array}{lll} \text{CAS Number} & 152121\text{-}30\text{-}7 \\ \text{Purity} & \geq 98\% \\ \text{Molecular Weight} & 331.34 \\ \text{Molecular Formula} & C_{20}H_{14}\text{FN}_3\text{O} \\ \end{array}$

SMILES FC1=CC=C(C2=C(C3=CC=NC=C3)NC(C4=CC=C(O)C=C4)=N2)C=C1

Target & IC50 = 14.3 nM (human); p38 MAP kinase: IC50 = 30 Nm; p38 β: IC50 = 100 nM

Toxoplasma gondii: IC50 = 1 μM

Shipping Gel Pack Storage Store at -20° C

Molecular Structure

Solubility

DMSO: 33.1 mg/mL (100 mM)

PS: < 1 mg/ml refers to the product insoluble

Product Description

SB 202190 is a selective and potent p38 MAP kinases inhibitor, binding to its ATP pocket. It has negligible inhibiting properties on other MAP kinases such as ERKs and JNKs. SB 202190 is reported to be used to induce cardiomyocyte differentiation from human embryonic stem cells and increase neural stem cell self-renewal.